News & Updates

Show Multimedia Only

Tiny implantable cooling device promises drug-free pain relief

28 Sep 2022 by

A soft, miniaturized bioresorbable implant that delivers focused, minimally invasive cooling power in living tissues can help alleviate pain on demand without the use of medications and may provide an alternative to opioids and other highly addictive painkillers.

28 Sep 2022

Tumour volume predicts pathologic complete response in rectal cancer patients

28 Sep 2022

In locally advanced rectal cancer patients on neoadjuvant chemoradiation, a tumour volume threshold of 37.3 cm3 is associated with pathologic complete response (pCR), suggests a recent study.

28 Sep 2022

Vision impairment tied to depression, anxiety in children

28 Sep 2022 by

Children with vision impairment are at higher risk of developing symptoms of depression and anxiety, according to a study, noting that surgical treatment of strabismus may improve these symptoms.

28 Sep 2022

Active surveillance with delayed intervention a safe, cheaper option for small renal masses

28 Sep 2022

Active surveillance (AS) along with timely delayed intervention (DI) is a safe and economical alternative to immediate intervention in patients with small renal masses (SRM), suggests a study.

28 Sep 2022

FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents

28 Sep 2022 by

A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.

28 Sep 2022

Temporary cessation of antithrombotic therapy before colonoscopy may do more harm than good

28 Sep 2022

Interrupting antithrombotic therapy among patients undergoing colonoscopy appears to contribute to higher thromboembolism (TE) events and even mortality, especially in high-risk patients, according to a study.

28 Sep 2022

First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer

27 Sep 2022

Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.